See more : Bentley Systems, Incorporated (BSY) Income Statement Analysis – Financial Results
Complete financial analysis of Abeona Therapeutics Inc. (ABEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abeona Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SPEL Semiconductor Limited (SPELS.BO) Income Statement Analysis – Financial Results
- MYR Group Inc. (MYRG) Income Statement Analysis – Financial Results
- Mitsubishi Chemical Group Corporation (4188.T) Income Statement Analysis – Financial Results
- Canadian GoldCamps Corp. (CAMP.CN) Income Statement Analysis – Financial Results
- Cipher Mining Inc. (CIFRW) Income Statement Analysis – Financial Results
Abeona Therapeutics Inc. (ABEO)
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.50M | 1.41M | 3.00M | 10.00M | 0.00 | 3.00M | 837.00K | 889.00K | 1.04M | 925.00K | 2.04M | 4.40M | 1.85M | 481.00K | 352.00K | 291.00K | 57.00K | 0.00 | 0.00 | 549.00K | 1.30M | 1.15M | 243.00K | 107.00K | 15.00K | 100.00K | 435.00K | 167.00K | 2.95M |
| Cost of Revenue | 1.61M | 450.00K | 4.46M | 30.14M | 8.68M | 38.70M | 16.99M | 10.66M | 0.00 | 0.00 | 125.00K | 267.00K | 1.22M | 140.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 239.00K | 277.00K | 107.00K | 0.00 | 0.00 | 0.00 | 0.00 | 580.00K | 8.31M | 0.00 |
| Gross Profit | 1.90M | 964.00K | -1.46M | -20.14M | -8.68M | -35.70M | -16.15M | -9.77M | 1.04M | 925.00K | 1.92M | 4.14M | 632.00K | 341.00K | 352.00K | 291.00K | 57.00K | 0.00 | 0.00 | 310.00K | 1.02M | 1.04M | 243.00K | 107.00K | 15.00K | 100.00K | -145.00K | -8.15M | 2.95M |
| Gross Profit Ratio | 54.14% | 68.18% | -48.80% | -201.39% | 0.00% | -1,190.79% | -1,929.75% | -1,098.54% | 100.00% | 100.00% | 93.88% | 93.94% | 34.20% | 70.89% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 56.47% | 78.61% | 90.67% | 100.00% | 100.00% | 100.00% | 100.00% | -33.33% | -4,878.44% | 100.00% |
| Research & Development | 31.09M | 28.97M | 34.33M | 30.14M | 48.57M | 38.70M | 16.99M | 10.66M | 4.72M | 333.00K | 884.00K | 2.01M | 4.20M | 3.35M | 2.66M | 12.61M | 2.60M | 2.05M | 2.78M | 5.42M | 6.10M | 7.02M | 4.17M | 4.01M | 1.61M | 1.80M | 2.43M | 1.41M | 1.25M |
| General & Administrative | 19.00M | 17.26M | 22.80M | 23.78M | 20.71M | 20.11M | 10.94M | 13.29M | 14.32M | 3.71M | 0.00 | 6.02M | 583.00K | 4.51M | 7.11M | 4.34M | 957.00K | 0.00 | 4.64B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.49M | 0.00 | 0.00 | 0.00 | 3.12M | 0.00 | -4.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.00M | 17.26M | 22.80M | 23.78M | 20.71M | 20.11M | 10.94M | 13.29M | 14.32M | 3.71M | 4.83M | 6.02M | 4.08M | 4.51M | 7.11M | 4.34M | 4.08M | 2.81M | 4.64M | 3.20M | 2.51M | 2.28M | 1.96M | 1.74M | 1.47M | 1.50M | 1.78M | 1.94M | 1.35M |
| Other Expenses | 0.00 | 141.00K | 3.25M | 4.59M | 7.82M | 2.36M | 741.00K | 825.00K | 551.00K | 3.72M | 4.84M | 419.00K | 4.31M | 238.00K | 259.00K | 253.00K | 4.36M | 3.12M | 6.84M | 3.97M | 3.14M | 2.72M | 2.38M | 2.16M | 1.76M | 1.70M | 1.95M | 2.06M | 1.35M |
| Operating Expenses | 49.03M | 46.22M | 60.37M | 58.50M | 77.09M | 61.16M | 28.67M | 24.77M | 19.59M | 4.06M | 5.72M | 8.45M | 8.51M | 8.10M | 10.03M | 17.21M | 6.96M | 5.18M | 9.62M | 9.39M | 9.23M | 9.74M | 6.55M | 6.17M | 3.36M | 3.50M | 4.38M | 3.47M | 2.60M |
| Cost & Expenses | 50.64M | 46.67M | 60.37M | 58.50M | 77.09M | 61.16M | 28.67M | 24.77M | 19.59M | 4.06M | 5.85M | 8.72M | 9.72M | 8.24M | 10.03M | 17.21M | 6.96M | 5.18M | 9.62M | 9.63M | 9.51M | 9.85M | 6.55M | 6.17M | 3.36M | 3.50M | 4.96M | 11.78M | 2.60M |
| Interest Income | 2.12M | 431.00K | 69.00K | 1.30M | 1.21M | 1.51M | 525.00K | 2.01M | 4.03M | 45.00K | 251.00K | 242.00K | 1.33M | 2.05M | 29.00K | 178.00K | 125.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 418.00K | 736.00K | 3.67M | 4.12M | 400.00K | 11.00K | 8.00K | 6.00K | 6.00K | 582.00K | 279.00K | 608.00K | 963.00K | 607.00K | 539.00K | 478.00K | 3.51M | 7.44M | 2.10M | 1.39M | 1.28M | 1.28M | 1.17M | 342.00K | 0.00 | 0.00 | 0.00 | 45.00K | 0.00 |
| Depreciation & Amortization | 3.20M | 4.58M | 4.46M | 5.60M | 8.68M | 2.36M | 741.00K | 825.00K | 551.00K | 11.00K | 3.00K | 419.00K | 233.00K | 238.00K | 259.00K | 253.00K | 2.60M | 7.06M | 1.57M | 1.08M | 898.00K | 686.00K | 627.00K | 476.00K | 285.00K | 200.00K | 162.00K | 123.00K | 15.00K |
| EBITDA | -50.57M | -34.38M | -76.80M | -74.52M | -67.61M | -54.31M | -26.58M | -21.05M | -13.97M | -26.19M | 4.73M | -9.51M | -1.32M | -6.69M | -16.54M | -16.48M | -18.12M | 2.99M | -7.56M | -4.93M | -4.53M | -8.01M | -5.68M | -5.58M | -3.06M | -3.30M | -4.36M | -11.49M | 356.00K |
| EBITDA Ratio | -1,444.91% | -3,160.18% | -1,801.70% | -426.17% | 0.00% | -1,811.21% | -3,174.43% | -2,366.93% | -1,343.17% | -332.43% | -173.85% | -82.99% | -341.40% | -1,309.77% | -642.90% | -5,664.60% | 12,847.37% | 0.00% | 0.00% | -1,457.74% | -564.86% | -698.69% | -2,337.86% | -5,216.82% | -20,426.67% | -3,200.00% | -1,030.11% | -6,997.60% | 12.09% |
| Operating Income | -47.14M | -45.26M | -89.84M | -81.42M | -77.09M | -58.17M | -27.84M | -23.88M | -18.55M | -3.13M | -3.80M | -4.32M | -7.88M | -7.76M | -9.68M | -16.92M | -6.90M | -5.18M | -9.62M | -9.08M | -8.21M | -8.70M | -6.31M | -6.06M | -3.35M | -3.40M | -4.52M | -11.61M | 341.00K |
| Operating Income Ratio | -1,346.71% | -3,200.64% | -2,994.53% | -814.20% | 0.00% | -1,940.16% | -3,325.69% | -2,686.28% | -1,783.27% | -338.49% | -186.29% | -98.00% | -426.19% | -1,612.68% | -2,748.86% | -5,812.71% | -12,105.26% | 0.00% | 0.00% | -1,653.73% | -634.21% | -758.50% | -2,595.88% | -5,661.68% | -22,326.67% | -3,400.00% | -1,040.00% | -6,953.89% | 11.58% |
| Total Other Income/Expenses | -7.05M | 11.22M | 4.90M | -2.81M | 808.00K | 1.50M | 517.00K | 2.01M | 4.02M | -23.65M | 8.25M | -6.22M | 5.36M | 220.00K | -7.15M | -300.00K | -15.02M | -8.25M | -4.07M | -1.16M | 1.79M | -684.00K | 281.00K | 630.00K | 41.00K | 0.00 | 83.00K | 151.00K | 0.00 |
| Income Before Tax | -54.19M | -39.70M | -84.94M | -84.23M | -76.28M | -56.67M | -27.32M | -21.87M | -14.53M | -26.78M | 4.45M | -10.53M | -2.52M | -8.98M | -16.83M | -17.22M | -21.92M | 13.42M | -11.62M | -10.24M | -6.94M | -9.38M | -6.03M | -5.43M | -3.31M | 0.00 | -4.44M | -11.46M | 341.00K |
| Income Before Tax Ratio | -1,548.23% | -2,807.36% | -2,831.20% | -842.34% | 0.00% | -1,890.29% | -3,263.92% | -2,460.40% | -1,396.73% | -2,894.92% | 217.87% | -239.15% | -136.09% | -1,866.11% | -4,781.25% | -5,915.81% | -38,450.88% | 0.00% | 0.00% | -1,864.85% | -535.52% | -818.13% | -2,480.25% | -5,072.90% | -22,053.33% | 0.00% | -1,020.92% | -6,863.47% | 11.58% |
| Income Tax Expense | 0.00 | -7.89M | 3.67M | 4.12M | 400.00K | 1.51M | 525.00K | 2.01M | 4.03M | 582.00K | 279.00K | 608.00K | 17.00K | -220.00K | 7.66M | 178.00K | -61.00K | -173.00K | -4.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -83.00K | -151.00K | 0.00 |
| Net Income | -54.19M | -31.81M | -88.61M | -88.35M | -76.68M | -56.67M | -27.32M | -21.87M | -14.53M | -26.78M | 4.45M | -10.53M | -2.53M | -7.54M | -17.34M | -17.22M | -21.86M | -12.87M | -1.70M | -10.24M | -6.94M | -9.38M | -6.03M | -5.43M | -3.31M | -3.40M | -4.44M | -11.46M | 341.00K |
| Net Income Ratio | -1,548.23% | -2,249.58% | -2,953.53% | -883.49% | 0.00% | -1,890.29% | -3,263.92% | -2,460.40% | -1,396.73% | -2,894.92% | 217.87% | -239.15% | -137.01% | -1,566.94% | -4,926.14% | -5,915.81% | -38,343.86% | 0.00% | 0.00% | -1,864.85% | -535.52% | -818.13% | -2,480.25% | -5,072.90% | -22,053.33% | -3,400.00% | -1,020.92% | -6,863.47% | 11.58% |
| EPS | -2.53 | -4.05 | -22.50 | -23.84 | -38.07 | -29.81 | -16.40 | -16.00 | -13.16 | -344.56 | 76.75 | -544.49 | -158.39 | -602.67 | -1.83K | -2.58K | -7.69K | -4.56K | -656.62 | -4.22K | -3.27K | -4.48K | -2.93K | -3.07K | -3.40K | -6.20K | -317.21K | -955.17K | 37.89K |
| EPS Diluted | -2.53 | -4.05 | -22.50 | -23.84 | -38.07 | -29.81 | -16.40 | -16.00 | -13.16 | -344.56 | 76.00 | -544.49 | -158.39 | -602.67 | -1.83K | -2.58K | -7.69K | -4.56K | -656.62 | -4.22K | -3.27K | -4.48K | -2.93K | -3.07K | -3.40K | -6.20K | -317.21K | -955.17K | 37.89K |
| Weighted Avg Shares Out | 21.38M | 7.86M | 3.94M | 3.71M | 2.01M | 1.90M | 1.67M | 1.37M | 1.10M | 77.72K | 20.19K | 19.34K | 15.99K | 12.51K | 9.45K | 6.68K | 2.84K | 2.83K | 2.59K | 2.43K | 2.12K | 2.10K | 2.06K | 1.77K | 974.00 | 548.00 | 14.00 | 12.00 | 9.00 |
| Weighted Avg Shares Out (Dil) | 21.38M | 7.86M | 3.94M | 3.71M | 2.01M | 1.90M | 1.67M | 1.37M | 1.10M | 77.72K | 20.38K | 19.34K | 15.99K | 12.51K | 9.45K | 6.68K | 2.84K | 2.83K | 2.59K | 2.43K | 2.12K | 2.10K | 2.06K | 1.77K | 974.00 | 548.00 | 14.00 | 12.00 | 9.00 |
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
CMS grants ICD-10-PCS product-specific procedure code and favorable DRG assignment for pz-cel, supporting efficient hospital billing, reimbursement and patient access CMS grants ICD-10-PCS product-specific procedure code and favorable DRG assignment for pz-cel, supporting efficient hospital billing, reimbursement and patient access
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
Significant progress addressing CMC items noted in CRL BLA resubmission remains on track for 2H 2024 CLEVELAND, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2024 and recent...
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones
Abeona Therapeutics Inc.'s BLA resubmission of Pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa is expected 2nd half of 2024. If Pz-cel is approved by the FDA, the company believes that it could reach peak U.S. sales...
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced...
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona's Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ:ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Source: https://incomestatements.info
Category: Stock Reports